Treatment of childhood kaposiform hemangioendothelioma with sirolimus

Julie Blatt, Joseph Stavas, Billie Moats-Staats, John Woosley, Dean S. Morrell

Research output: Contribution to journalArticlepeer-review

123 Scopus citations


Sirolimus (Rapamune), a mammalian target of Rapamycin (mTOR) inhibitor, which has been used extensively in children following solid organ transplantation, has been demonstrated to have anti-angiogenic activity in pre-clinical models. Limited experience suggests that it may have application to the treatment of vascular lesions. We describe our experience with a 1-year-old female with a kaposiform hemangioendothelioma and Kasabach-Merritt phenomenon who had rapid and dramatic response to sirolimus (0.1mg/kg/day). This case provides further rationale for clinical trials of sirolimus in the treatment of vascular lesions.

Original languageEnglish
Pages (from-to)1396-1398
Number of pages3
JournalPediatric Blood and Cancer
Issue number7
StatePublished - Dec 2010
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pediatrics, Perinatology, and Child Health
  • Hematology


Dive into the research topics of 'Treatment of childhood kaposiform hemangioendothelioma with sirolimus'. Together they form a unique fingerprint.

Cite this